Member Info for busicat

Surprisingly quiet here, given results due next Wednesday followed by the presentation on Friday.

Nice trend developing from recent low...

Re-rate now in train?

Results next Wednesday after hours and webinar 5pm should be intereting. The sound business model, customer proposition, steadily growing loyal customer base, AUM, revenue and expansion with great partners in the US is what keeps me coming back to this one, even though share price moves can be boring.

Yes, Stockkid and two Merck scientists, plus one at AstraZenca along with two senior folk at the latter...

Oh dear. Update looked nice at first glance until the profit warning in the middle. Was about to swoop on what I thought a bargain, but maybe hold off a bit now. I wonder it's cheap enough for jollyspeculator now!

Market seems happy

The board expects to trade in line with market expectations for FY to Fab 2026, being "revenue of £335.9m and profit before taxation and highlighted items of £41.6m".

Whoops, 30th is what I should have said - more haste, less speed

Results notice just out will hopefully stir up some interest in the lead up

"Looking like the bottom is in……..could see a bit of a rally from here"

I hope you're right and it looks like it comparing April lows. But then it looked like a bargain at 3.6 and 3.1 to me, so "looks like it to me" is no good indicator from Yours Truly.

Excellent, thanks John

"This a unique opportunity to be an integral part of a newly funded national roll-out of Pharmacogenetics Point of Care Testing (POCT). The POCT market is increasing rapidly, offering new and innovative solutions to healthcare, this post will support the ANIA (Accelerated National Innovation Adoption) implementation of MT-RNR1 genetic testing at the point of care, for newborn babies < 28 days old."

Easy profit here for anyone who bought on the Tues/Weds dip, whatever all that was about!

What yesterday's trailing of the event didn't highlight, but is confirmed today is that Gino Will not just be out their marketing stand but will be presenting too as a keynote speaker. : )

Yesterday there was a LinkedIn post saying "TOMORROW you can find Gino Miele and Stacey Gardiner at the ONE BioHub Innovate MedTech North Conference in Aberdeen!"

Today Genedrive posts that:

"TODAY Gino Miele and Stacey Gardiner are all set up on the genedrive stand, at the ONE BioHub Innovate MedTech North Conference in Aberdeen!

Where our CEO Dr. Gino Miele will be delivering a keynote speech, on how our innovative pharmacogenetic tests are being used in routine clinical practice to guide personalised medicine.​"

Meanwhile the team working hard at keeping visibility up

"TOMORROW you can find Gino Miele and Stacey Gardiner at the ONE BioHub Innovate MedTech North Conference in Aberdeen!"

27/6 Berenberg raises ConvaTec price target to 335 (310) pence - 'buy'.

Maybe that was the kiss of death!

...plummeting today and yesterday? There seems to be a big sell off for some reason.

Nice find, thanks Lionel!

Outlook "2025 is set to be a record year for Audioboom, and we have made a positive start in the first three months, delivering 10X adjusted EBITDA growth (US$0.7 million vs. Q1 2024: US$0.07 million)."

2024 Financial results

"The total profit before tax for the year was US$0.9 million, a significant improvement on the prior year (2023: US$16.8 million total loss before tax) mainly due to the US$7.4 million provision for the future estimated net loss of the two onerous contracts and the US$5.1 million loss incurred on those contracts in 2023. The Company saw a cash inflow from operating activities of US$0.1 million (2023: cash outflow of US$4.5 million), mainly due to the improvement in trading year on year. The Company continues to operate an extremely efficient working capital cycle which is now well established in terms of processes built and refined over the last six years.

Debtor collections continue to be strong and, over the last five years, collections have averaged 96% of revenue recognised in the year. In 2024, debtor days of 82 are reported, 1 higher than the 81 reported in 2024 - we continue to remain below our ongoing debtor day target of 90 days. The Company continues to incur very minimal bad debt write offs (US$0.1 million in both 2024 and 2023) and average payable days increased to 82 in 2024 from 68 in 2023, reflecting the return to revenue growth in Q4 2024 which led to an increase in year-end partner payments that have been satisfied in Q1 2025.

The Company ended 2024 with cash of US$3.9 million.

In addition, the Company had access to a US$3.1 million overdraft facility with HSBC which was increased from US$1.9 million in November 2024. Therefore, the Company had access to circa US$7.0 million going into 2025, with the Company being fully funded for its current growth trajectory."

I'm happy with that

Thanks for posting the link, Stringerbell.

£1,004k orders received in FY2024 and order book for Q1 2025 higher than the sales achieved H1 2024 sounds hopeful for translation to revenue received if this momentum continues.

If the Q1 run rate doubling was replicated throughout 2025, and order value gets to £2m FY0225, this feels more hopeful vs the 2024 yearly fixed costs of £1.6m due to be reduced in 2025.

"The company is seeing early commercial traction, with installations in UK hospitals and international sites, including Saudi Arabia."